News | October 12, 2021
Tarsons earmarks funds from IPO to double capacity at its Panchla facility
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Subscribe To Our Newsletter & Stay Updated
